Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Immunol. 2022 Jul 8;13:907733. doi: 10.3389/fimmu.2022.907733. eCollection 2022.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint damage and even disability. Although there are various clinical therapies for RA, some patients still have poor or no response. Thus, the development of new drug targets remains a high priority. In this review, we discuss the role of G-protein-coupled receptors (GPCRs), including chemokine receptors, melanocortin receptors, lipid metabolism-related receptors, adenosine receptors, and other inflammation-related receptors, on mechanisms of RA, such as inflammation, lipid metabolism, angiogenesis, and bone destruction. Additionally, we summarize the latest clinical trials on GPCR targeting to provide a theoretical basis and guidance for the development of innovative GPCR-based clinical drugs for RA.
类风湿关节炎(RA)是一种慢性炎症性疾病,可导致关节损伤甚至残疾。虽然有各种针对 RA 的临床治疗方法,但一些患者的反应仍不佳或没有反应。因此,开发新的药物靶点仍然是当务之急。在这篇综述中,我们讨论了 G 蛋白偶联受体(GPCR),包括趋化因子受体、黑色素皮质素受体、脂质代谢相关受体、腺苷受体和其他炎症相关受体,在 RA 的炎症、脂质代谢、血管生成和骨破坏等机制中的作用。此外,我们总结了 GPCR 靶向的最新临床试验,为开发基于 GPCR 的创新 RA 临床药物提供了理论依据和指导。